Beta-Blockers Do Not Reduce Mortality in HFpEF and Are Not Recommended as Disease-Modifying Therapy
Beta-blockers have not been proven to reduce mortality in HFpEF and should only be used when specific comorbid indications exist (atrial fibrillation, post-MI within 3 years, angina, or uncontrolled hypertension). They are not guideline-directed medical therapy for HFpEF itself 1, 2.
Evidence Against Beta-Blockers for HFpEF
The evidence base reveals a critical distinction between observational data and randomized controlled trials:
Randomized trials show no benefit: Two RCTs demonstrated that beta-blockers were not associated with reduced all-cause mortality (RR 0.94,95% CI 0.67-1.32) or HF hospitalization (RR 0.90,95% CI 0.54-1.49) in HFpEF 3
Observational studies are misleading: While observational studies suggest mortality benefit (HR 0.81,95% CI 0.73-0.90), these findings likely reflect confounding by indication—patients receiving beta-blockers had other compelling indications like coronary disease 4, 3, 5
Contemporary trials reveal high baseline use: In major HFpEF trials (EMPEROR-PRESERVED, PARAGON, DELIVER), 80-90% of patients were already on beta-blockers at baseline for comorbid conditions, yet these agents were not the intervention being studied 6, 1
The Canadian guidelines explicitly state there is no indication for beta-blockers in managing HFnrEF (LVEF >40%), as no RCT has shown benefit in this population 2.
Recommended Pharmacologic Agents for HFpEF
First-Line Therapy (Class I Recommendations)
1. SGLT2 Inhibitors (Dapagliflozin or Empagliflozin)
- Strongest evidence for mortality and hospitalization reduction 7, 1
- DELIVER trial: HR 0.82 (0.73-0.92) for composite of worsening HF and CV death 1
- EMPEROR-PRESERVED: HR 0.79 (0.69-0.90) for HF hospitalization and CV death 1
- Start immediately upon diagnosis in all eligible patients
2. Loop Diuretics
- For symptom management and congestion control (Class I, Level B) 8
- Titrate to achieve euvolemia, then adjust to lowest effective dose
- Monitor for dehydration and renal dysfunction
3. Mineralocorticoid Receptor Antagonists (Spironolactone)
- Reduces HF hospitalization (OR 0.81,95% CI 0.66-0.98) 9
- TOPCAT showed benefit in North American cohort (HR 0.82,95% CI 0.69-0.98) 1
- Monitor potassium and renal function closely
Second-Line Add-On Therapy
4. Angiotensin Receptor-Neprilysin Inhibitor (Sacubitril/Valsartan)
- PARAGON-HF: Rate ratio 0.87 (0.75-1.01) for total HF hospitalizations and CV death 1
- Reduces HF hospitalization (OR 0.77,95% CI 0.63-0.94) 9
- Consider for patients remaining symptomatic despite SGLT2i and MRA
5. Angiotensin Receptor Blockers (Candesartan)
- Preferred renin-angiotensin system inhibitor if ARNI not used 2
- CHARM-Preserved: HR 0.86 (0.74-1.00) for HF hospitalization and CV death 1
- Particularly useful for blood pressure control
6. GLP-1 Receptor Agonists (Semaglutide 2.4 mg weekly)
- For obese patients with HFpEF (BMI ≥30 or ≥27 with comorbidities) 2
- Improves symptoms, exercise capacity, and quality of life
- Titrate slowly over 16 weeks to minimize gastrointestinal side effects
- Monitor for muscle loss; encourage protein intake and resistance exercise
Treatment Algorithm
Step 1: Initiate SGLT2 inhibitor + loop diuretic (if congested)
Step 2: Add MRA if symptomatic despite Step 1
Step 3: Consider ARNI or ARB if still symptomatic
Step 4: Add GLP-1 RA if obese (BMI ≥30)
Step 5: Optimize blood pressure control (target <130/80 mmHg) 8
Critical Caveats
Avoid diltiazem and verapamil in HFrEF (Class III) but may be used cautiously in HFpEF for rate control 8
ACE inhibitors have not shown benefit in HFpEF specifically (PEP-CHF and I-PRESERVE trials were neutral) 10, 1
Beta-blockers may worsen exercise tolerance due to chronotropic incompetence; monitor functional capacity if prescribed for comorbidities 1
Target doses matter: Use evidence-based doses from clinical trials (e.g., dapagliflozin 10 mg daily, empagliflozin 10 mg daily, spironolactone 25-50 mg daily) 1
The paradigm has shifted dramatically with SGLT2 inhibitors emerging as the cornerstone of HFpEF therapy, while beta-blockers remain relegated to treating specific comorbid conditions rather than HFpEF itself.